• Je něco špatně v tomto záznamu ?

A pilot randomized trial comparing long-term effects of red and white wines on biomarkers of atherosclerosis (in vino veritas: IVV trial)

M. Taborsky, P. Ostadal, M. Petrek,

. 2012 ; 113 (3) : 156-8.

Jazyk angličtina Země Slovensko

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc12023984

BACKGROUND: Since early 90', growing body of evidence indicates that the Mediterranean diet with mild to moderate consumption of wine, mostly red wine, has a protective effect on cardiovascular diseases. Several mechanisms have been discussed to participate in the beneficial effect of red wine, such as antioxidant or vasodilating activity. However, later it has been shown that also other alcoholic beverages have a protective effect on atherosclerosis. Up to now, data from the prospective, long-term, head-to-head comparisons of the effects of different drinks on markers of atherosclerosis are insufficient. METHODS: The IVV (in vino veritas) study is a long-term, prospective, multicenter, randomized trial comparing the effect of red and white wines on the markers of atherosclerosis. One hundred and twenty healthy subjects with mild to moderate risk of atherosclerosis will be randomized to regular consumption of red wine (Pinot Noir) or white wine (Chardonnay-Pinot) for one year. The primary endpoint is the level of HDL-cholesterol at one year, while secondary endpoints are levels of other markers of atherosclerosis (LDL-cholesterol, C-reactive protein, myeloperoxidase, advanced oxidation protein product, interleukins 6 and 18, matrix metalloproteinases, glutathione s-transferase, monocyte chemoattractant protein 1, soluble CD40L). CONCLUSION: The IVV trial is the first study focusing on the long-term prospective comparison of the effects of red and white wines consumption on HDL-cholesterol and other markers of atherosclerosis. Results of the IVV trial may extend our understanding of the widely discussed "French paradox" (Tab. 1, Ref. 21)

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12023984
003      
CZ-PrNML
005      
20121206122412.0
007      
ta
008      
120815s2012 xo f 000 0#eng||
009      
AR
024    7_
$a 10.4149/bll_2012_037 $2 doi
035    __
$a (PubMed)22428764
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Taborsky, M $u Olomouc University Hospital, Olomouc, Czech Republic. milos.taborsky@fnol.cz
245    12
$a A pilot randomized trial comparing long-term effects of red and white wines on biomarkers of atherosclerosis (in vino veritas: IVV trial) / $c M. Taborsky, P. Ostadal, M. Petrek,
520    9_
$a BACKGROUND: Since early 90', growing body of evidence indicates that the Mediterranean diet with mild to moderate consumption of wine, mostly red wine, has a protective effect on cardiovascular diseases. Several mechanisms have been discussed to participate in the beneficial effect of red wine, such as antioxidant or vasodilating activity. However, later it has been shown that also other alcoholic beverages have a protective effect on atherosclerosis. Up to now, data from the prospective, long-term, head-to-head comparisons of the effects of different drinks on markers of atherosclerosis are insufficient. METHODS: The IVV (in vino veritas) study is a long-term, prospective, multicenter, randomized trial comparing the effect of red and white wines on the markers of atherosclerosis. One hundred and twenty healthy subjects with mild to moderate risk of atherosclerosis will be randomized to regular consumption of red wine (Pinot Noir) or white wine (Chardonnay-Pinot) for one year. The primary endpoint is the level of HDL-cholesterol at one year, while secondary endpoints are levels of other markers of atherosclerosis (LDL-cholesterol, C-reactive protein, myeloperoxidase, advanced oxidation protein product, interleukins 6 and 18, matrix metalloproteinases, glutathione s-transferase, monocyte chemoattractant protein 1, soluble CD40L). CONCLUSION: The IVV trial is the first study focusing on the long-term prospective comparison of the effects of red and white wines consumption on HDL-cholesterol and other markers of atherosclerosis. Results of the IVV trial may extend our understanding of the widely discussed "French paradox" (Tab. 1, Ref. 21)
650    _2
$a ateroskleróza $x diagnóza $7 D050197
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a HDL-cholesterol $7 D008076
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a výzkumný projekt $7 D012107
650    _2
$a víno $x analýza $7 D014920
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Ostadal, P
700    1_
$a Petrek, M
773    0_
$w MED00000845 $t Bratislavské lekárske listy $x 0006-9248 $g Roč. 113, č. 3 (2012), s. 156-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22428764 $y Pubmed
910    __
$a ABA008 $b A 4 $c sign $y m
990    __
$a 20120815 $b ABA008
991    __
$a 20121206122445 $b ABA008
999    __
$a ok $b bmc $g 946132 $s 781312
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 113 $c 3 $d 156-8 $i 0006-9248 $m Bratislavské lekárske listy $n Bratisl Lek Listy $x MED00000845
LZP    __
$a Pubmed-20120815/12/02

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...